Target intelligence / Profile preview

Cytomegalovirus 65 kDa phosphoprotein (pp65) peptide epitopes (CMV pp65)

Target
CMV pp65
Molecular classification
Viral protein, Antigen, Other
01

Overview

Cytomegalovirus (CMV) 65 kDa phosphoprotein (pp65), encoded by the UL83 gene, is an abundant tegument protein of human cytomegalovirus (HCMV). It plays a critical role in viral replication and immune evasion by counteracting host antiviral responses, such as inhibiting interferon regulatory factor 3 (IRF3) and cGAS-STING signaling. Because pp65 is highly immunogenic, its peptide epitopes (such as the HLA-A*02:01-restricted NLVPMVATV) are major targets of the host cellular immune response, eliciting robust CD4+ and CD8+ T-cell activation. In clinical therapeutics, these peptide epitopes are targeted to prevent or treat CMV reactivation in immunocompromised individuals, such as transplant recipients, and are also investigated as tumor-associated antigens in cancers like glioblastoma. Therapeutic strategies include peptide-based vaccines (e.g., CMVPepVax, PEP-CMV) that stimulate endogenous T-cell immunity, and adoptive immunotherapies (e.g., TCR-T cells) that utilize pp65-specific T cells to eliminate infected or malignant cells.

Other names
CMV pp65 peptide epitopesCytomegalovirus pp65 peptide epitopesHuman cytomegalovirus pp65 peptide epitopesHCMV pp65 peptide epitopesUL83 peptide epitopes65 kDa phosphoprotein peptide epitopes65 kDa matrix phosphoprotein peptide epitopesTegument protein UL83 peptide epitopesNLVPMVATVQYDPVAALF
02

Mechanism of action

Drugs targeting CMV pp65 peptide epitopes act primarily as vaccines or adoptive immunotherapies. Peptide vaccines (such as CMVPepVax and PEP-CMV) deliver these immunodominant epitopes to antigen-presenting cells, which present them on HLA molecules to stimulate and expand endogenous CMV-specific CD4+ and CD8+ T cells. Adoptive cell therapies, including TCR-T cells and CMV-specific cytotoxic T lymphocytes, utilize these epitopes to select, expand, or genetically engineer T cells in vitro, which are then infused into patients to directly target and eliminate CMV-infected cells or tumor cells expressing pp65.

03

Biological functions

Immune responseOther
04

Disease associations

InfectionCancerOther
05

Safety considerations

Cytokine release syndromeGraft-versus-host diseaseInjection site reactionsCerebral edemaEncephalopathyHLA restriction limitations
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

HLA-A*02:01HLA-A*24:02CMV serostatusIFN-gamma ELISpotCMV viral load

Beyond the preview

Go deeper on Cytomegalovirus 65 kDa phosphoprotein (pp65) peptide epitopes (CMV pp65).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytomegalovirus 65 kDa phosphoprotein (pp65) peptide epitopes (CMV pp65).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call